Elsevier

The Journal of Pediatrics

Volume 89, Issue 3, September 1976, Pages 467-470
The Journal of Pediatrics

A prospective controlled trial of oral kanamycin in the prevention of neonatal necrotizing enterocolitis**

https://doi.org/10.1016/S0022-3476(76)80553-7Get rights and content

Alimentary kanamycin, 15 mg/kg/day, was given as prophylaxis for neonatal necrotizing enterocolitis in a prospective study. Newborn infants of less than 1,500 gm birth weight who survived until initiation of alimentary nutrition at the University of Florida Neonatal Intensive Care Unit were admitted to a control or study group based on the last digit of the hospital number. Alimentary kanamycin was not absorbed; all blood levels determined were less than 0.5 μg/ml. The two groups had similar gestational ages, birth weights, severity of neonatal illness, and frequency of therapeutic procedures. In the study group of 35 infants, none developed neonatal necrotizing enterocolitis, whereas five cases occurred in the 40 control infants (p=0.038).

Cited by (92)

  • Impact of Antibiotics on Necrotizing Enterocolitis and Antibiotic-Associated Diarrhea

    2017, Gastroenterology Clinics of North America
    Citation Excerpt :

    Several older randomized controlled trials (RCTs),53 as well as animal studies, have shown that prophylactic administration of enteral antibiotics can prevent this disease.49 Five RCTs have been conducted to evaluate the use of prophylactic enteral antibiotics (gentamicin, vancomycin, and kanamycin) for the prevention of NEC, all demonstrating significant reductions in rates of NEC,53–57 with a subsequent meta-analysis showing an almost 50% reduction in the rates of NEC and a 70% reduction in NEC-related deaths.58 However, these studies have limitations.

  • Necrotizing enterocolitis and preterm infant gut bacteria

    2016, Seminars in Fetal and Neonatal Medicine
    Citation Excerpt :

    Aminoglycosides would be active against Gammaproteobacteria in the gut, but not suppress anaerobic bacterial populations. In the aggregate, these studies [41–44] support the use of oral aminoglycosides to prevent NEC. However, because of concerns about selecting for aminoglycoside-resistant organisms [45] and of absorption of the oral aminoglycosides from the gut (which occurs during the very earliest in life interval before the incidence of NEC increases [46]), enteral antibiotics to prevent NEC are not widely used.

  • Focal Bacterial Infections

    2011, Infectious Diseases of the Fetus and Newborn Infant
  • Focal bacterial infections

    2010, Infectious Diseases of the Fetus and Newborn: Expert Consult - Online and Print
  • Focal Bacterial Infections

    2006, Infectious Diseases of the Fetus and Newborn Infant
  • Clinical Pharmacology of Antibacterial Agents

    2006, Infectious Diseases of the Fetus and Newborn Infant
View all citing articles on Scopus
**

Supported in part by National Institutes of Health grant HD 00054-14.

View full text